Home・Lista de Ações・Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Fechado

SetorSaúde

4.13 -3.5

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.12

Máximo

4.28

Indicadores-chave
By Trading Economics
Rendimento	11M 51M
Vendas	6.5M 113M
P/E Médio do Setor	5.45 57.371
EPS	0.31
Margem de lucro	45.374
Funcionários	100
EBITDA	6.2M 81M

Dividendos
By Acuity
Próximos Ganhos	9 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-7.1M 720M
Abertura anterior	7.63
Fecho anterior	4.13

Sentimento de Notícias

By Acuity

32%

68%

104 / 340 Ranking em Healthcare

Ironwood Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de ago. de 2026, 21:51 UTC

Ironwood Pharmaceuticals Inc shares are higher in after-market trading, reaching the upper end of their one-month trading range. No specific news was identified.

20 de ago. de 2026, 20:06 UTC

Ironwood Pharmaceuticals Inc shares are lower during Thursday's session, reversing earlier gains amid rising crude oil prices and increasing U.S. Treasury yields.

19 de ago. de 2026, 19:46 UTC

Ironwood Pharmaceuticals shares are higher, supported by declining bond yields and broader market trends. The stock is trading near the upper end of its one-month range.

18 de ago. de 2026, 19:36 UTC

Ironwood Pharmaceuticals Inc shares are lower today amid cautious market sentiment influenced by rising treasury yields and inflation concerns.

17 de ago. de 2026, 19:36 UTC

Ironwood Pharmaceuticals Inc is trading higher, maintaining its position near the upper end of its one-month range amid rising Treasury yields and inflation concerns.

14 de ago. de 2026, 23:01 UTC

Ironwood Pharmaceuticals shares declined in after-market trading, following a drop in U.S. retail sales that raised concerns about consumer spending and economic health.

13 de ago. de 2026, 23:36 UTC

Ironwood Pharmaceuticals Inc shares are lower during after-market hours, with no specific news identified to explain the decline. Trading activity remains routine.

12 de ago. de 2026, 19:21 UTC

Ironwood Pharmaceuticals is higher Wednesday, buoyed by overall strength in U.S. stocks, despite a recent pullback earlier in the session.

11 de ago. de 2026, 22:06 UTC

Ironwood Pharmaceuticals Inc shares are higher in after-market trading, with no specific news identified to explain the movement. The stock remains above its 20-day moving average.

10 de ago. de 2026, 19:36 UTC

Ironwood Pharmaceuticals Inc shares are lower today, with no specific news identified. The stock remains significantly down since Friday's close amid broader market volatility.

7 de ago. de 2026, 19:46 UTC

Ironwood Pharmaceuticals Inc shares are higher during Friday's session, maintaining a position above the 20-day moving average, despite earlier fluctuations.

6 de ago. de 2026, 23:06 UTC

Ironwood Pharmaceuticals shares are higher in after-market hours, reflecting positive movement since Thursday's close. No specific news was identified to explain the price action.

5 de ago. de 2026, 23:02 UTC

Ironwood Pharmaceuticals shares are higher in after-market trading, continuing a notable increase since Wednesday's close, despite no specific news identified.

4 de ago. de 2026, 23:01 UTC

Ironwood Pharmaceuticals Inc. shares are lower in after-market trading, showing routine volatility while remaining above the 20-day moving average. No specific news was identified.

3 de ago. de 2026, 19:26 UTC

Ironwood Pharmaceuticals is trading higher today, continuing a rally since Friday's close, amid broader market gains and falling energy prices.

31 de jul. de 2026, 23:26 UTC

Ironwood Pharmaceuticals Inc shares are trading higher in after-market hours, maintaining upward momentum since Friday's close. No specific news was identified for this movement.

30 de jul. de 2026, 20:51 UTC

Ironwood Pharmaceuticals shares declined in after-market trading, despite broader market gains. The stock remains below its 20-day moving average and near a one-month low.

29 de jul. de 2026, 20:04 UTC

Ironwood Pharmaceuticals Inc shares are trading lower amid broader market dynamics, including rising oil prices due to escalating Middle East tensions.

27 de jul. de 2026, 20:06 UTC

Ironwood Pharmaceuticals shares are higher today, reflecting broader market dynamics, despite earlier declines and a significant drop in oil prices.

24 de jul. de 2026, 23:26 UTC

Ironwood Pharmaceuticals shares gained modestly in after-market trading, following a volatile session amid broader turmoil in the bond market.

20 de jul. de 2026, 18:36 UTC

Ironwood Pharmaceuticals Inc is trading higher, reaching a session peak before settling within its one-month range. No specific news was identified for today's movement.

Comparação entre Pares

Variação de preço

Ironwood Pharmaceuticals Inc Previsão

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para Ironwood Pharmaceuticals Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

104 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.